紫杉醇或多西他赛联合奈达铂在宫颈癌新辅助化疗中的疗效及安全性
The efficacy and safety of paclitaxel or docetaxel combined with nedaplatin in the neoadjuvant chemotherapy of cervical cancer
-
摘要: 目的：评价紫杉醇或多西他赛分别联合奈达铂用于Ⅰb2~Ⅱb期宫颈癌病人行根治术前新辅助化疗的疗效及安全性。方法：选择经病理确诊的48例Ⅰb2~Ⅱb期宫颈癌病人作为研究对象，根据化疗方案不同分为紫杉醇+奈达铂组24例，多西他赛+奈达铂组24例，分别于根治性子宫切除术前/根治性放疗前行辅助化疗1个周期，比较2种化疗方案的疗效和不良反应。结果：紫杉醇+奈达铂组总有效率和多西他赛+奈达铂组总有效率分别为83.33%和79.17%，差异无统计学意义（P>0.05）；紫杉醇+奈达铂组完全缓解率（29.17%）高于多西他赛+奈达铂组（16.67%），但差异无统计学意义（P>0.05）；2组手术切除率均为100%，紫杉醇+奈达铂组术后病理不良预后高危因素发生率为33.33%，多西他赛+奈达铂组为16.67%；紫杉醇+奈达铂组术后3年无瘤生存率和3年总生存率分别为91.67%和95.83%，多西他赛+奈达铂组分别为87.50%和95.83%，2组差异均无统计学意义（P>0.05）；2组化疗不良反应总发生率差异无统计学意义（P>0.05）。结论：紫杉醇或多西他赛分别联合奈达铂用于Ⅰb2~Ⅱb期宫颈癌术前新辅助化疗安全有效，2种化疗方案疗效相近，不良反应相似，病人均可以耐受。Abstract: Objective:To evaluate the efficacy and safety of the neoadjuvant chemotherapy of paclitaxel or docetaxel combined with nedaplatin in stage Ⅰb2~Ⅱb cervical cancer.Methods:A total of 48 patients with stageⅠb2~Ⅱb cervical cancer diagnosed by pathology were investigated,and divided into the paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group(24 cases each group).The paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were treated with neoadjuvant chemotherapy for 1 cycle before radical hysterectomy and radical radiation therapy,respectively.The clinical effect and adverse reaction between two groups were compared.Results:The total effective rates in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 83.33% and 79.17%,respectively,and the difference of which was not statistically significant(P>0.05).The complete remission rates in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 29.17% and 16.67%,respectively,and the difference of which was not statistically significant(P>0.05).The excision rate in two groups was 100%.The incidence rates of high risk factors of postoperative adverse prognosis in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 33.33% and 16.67%,respectively.The 3-year free tumor survival rates and overall survival rates in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 91.67% ＆ 95.83% and 87.50% ＆ 95.83%,respectively,and the differences of which were not statistically significant(P>0.05).The difference of the total incidence rate of adverse reaction between two groups was not statistically significant(P>0.05).Conclusions:The neoadjuvant chemotherapy of paclitaxel or docetaxel combined with nedaplatin in stage Ⅰb2~Ⅱb cervical cancer is safe and effective.The clinical effect and adverse reaction of two methods are similar,and patients can tolerate.
-
Key words:
- cervical neoplasms /
- neoadjuvant chemotherapy /
- nedaplatin /
- paclitaxel /
- docetaxel
-
[1] DE AZEVEDO CR,THULER LC,DE MELLO MJ,et al.Neoadjuvant chemotherapy rollowed by chemoradiation in cervical carcinoma:a review[J].Int J Gynecol Cancer,2016,26(4):729. [2] SINGH U,AHIRWAR N,RANI AK,et al.The efficacy and safety of neoadjuvant chemotherapy in treatment of locally advanced carcinoma cervix[J].J Obstet Gynecol India,2013,64(4):273. [3] ANGIOLI R,PLOTTI F,LUVERO D,et al.Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced carcinoma cancer:a pilot study[J].Tumor Biol,2014,35(3):2741. [4] YAMAGUCHI S,NISHIMURA R,YAEGASHI N,et al.Phase Ⅱ study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ⅰb2 to Ⅱb,cervical squamous cell carcinoma:Japanese Gynecologic Oncology Group study (JGOG 1065)[J].Oncol Rep,2012,28(2):487. [5] SHOJI T,TAKATORI E,SAITO T,et al.Neoadjuvant chemotherapy using platinum-and taxane-based regimens for bulky stage Ⅰb2 to Ⅱb non-squamous cell carcinoma of the uterine cervix[J].Cancer Chemother Pharmacol,2013,71(3):657. [6] PRUEKSARITANOND N,CHAISARN P,YANARANOP M.The efficacy of neoadjuvant paclitaxel-carboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage ⅠB-ⅡA cervical cancer[J].J Med Assoc Thai,2012,95(Suppl 3):S55. [7] MIZUNUMA M,YOKOYAMA Y,FUTAGAMI M,et al.The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J].Int J Clin Oncol,2015,20(5):1. [8] HOSAKA M,WATARI H,KATO T,et al.Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy[J].J Surg Oncol,2012,105(6):612. [9] SONODA K,YAHATA H,ICHINOE A,et al.Retrospective Analysis of Concurrent Chemoradiation with Ariweekly Cisplatin plus 5-Fluorouracil Ersus Weekly Cisplatin in Cervical Cancer[J].Anticancer Res,2015,35(6):3447. -
点击查看大图
计量
- 文章访问数: 4743
- HTML全文浏览量: 674
- PDF下载量: 76
- 被引次数: 0
下载:
